**Core Concept**
Allergic Bronchopulmonary Aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus fumigatus, leading to bronchiectasis, asthma, and other respiratory complications in atopic individuals. This condition is characterized by an abnormal immune response to Aspergillus antigens, resulting in the release of cytokines and eosinophils.

**Why the Correct Answer is Right**
The correct answer is related to the diagnosis and pathophysiology of ABPA. ABPA is typically seen in patients with pre-existing asthma or cystic fibrosis, and it is associated with the presence of Aspergillus fumigatus in the sputum. The condition is characterized by an increase in IgE antibodies against Aspergillus antigens, which triggers an inflammatory response in the lungs. The key enzymes and pathways involved in ABPA include the release of eosinophilic cationic protein (ECP) and the activation of T-lymphocytes.

**Why Each Wrong Option is Incorrect**
**Option A:** ABPA is not typically seen in patients with normal lung function. This statement is incorrect because ABPA can occur in individuals with normal lung function, especially those with atopic disorders such as asthma.

**Option B:** Aspergillus fumigatus is not a common fungus in the environment. This statement is incorrect because Aspergillus fumigatus is a ubiquitous fungus that can be found in soil, water, and decaying organic matter.

**Option C:** Corticosteroids are not effective in treating ABPA. This statement is incorrect because corticosteroids are a mainstay of treatment for ABPA, helping to reduce inflammation and suppress the immune response.

**Clinical Pearl / High-Yield Fact**
A key clinical correlation is that ABPA often presents with a "central bronchiectasis" pattern on high-resolution computed tomography (HRCT) scans, which can help distinguish it from other causes of bronchiectasis.

**Correct Answer:** None of the above (all options are incorrect)